Sunday, May 20, 2018
Company News: Page (1) of 1 - 02/12/18 Email this story to a friend. email article Print this page (Article printing at page facebook
Pharmacogenomics Market Key Trend, Value Chain Analysis and Forecast till 2023; Says 23andMe Inc., Pathway Genomics, Teva Pharmaceutical

(February 12, 2018)

"Pharmacogenomics Market"
Global Pharmacogenomics Market Information by Application, By Therapeutic application (cancer, oncology, cardiovascular) By Methods (haplotype analysis, multivariate techniques) - Forecast to 2027

The Global Pharmacogenomics Market is expected to grow at a ~CAGR of 5.8% during the forecast period.

The pharmacogenomics market is growing at an incremental pace of development on the global stage due to the large number of advantages associated to personalized therapy. Market Research Future, a firm which specializes in market reports related to the healthcare sector among others, recently forecasted in its report on Global Pharmacogenomics Market Research Report- Forecast to 2023 that the market will demonstrate an exceptional CAGR ~5.8 % while achieving million dollar growth readily in the forecast period.

Pharmacogenomics is one of the basic components in customized pharmaceutical. The basic idea in pharmacogenomics is that interindividual fluctuation in tranquilize reaction is an outcome of different variables, including genomics, epigenomics, the earth and a patient's attributes, for example, sexual orientation, age as well as attendant medicine.

Pharmacogenomics assumes a vital part in tranquilize revelation and improvement. Pharmacogenomics alludes to the impacts of hereditary polymorphism and genomic variations on tranquilize reaction, its data can help in determination of the ideal medication, measurements, treatment process, and maintain a strategic distance from unfavorable medication responses. As antagonistic medication responses have been accounted for as one of the main sources of death among hospitalized patients. Unfriendly medication responses are additionally alluded as the factor behind loss of trust in the social insurance framework and the reducing fulfillment of the two patients and wellbeing experts.

Access Free Sample Copy @ .

Latest Industry Updates

Nov 2017: Myriad Genetics, Inc., announced positive results from a double-blind, multi-center, randomized controlled trial assessing the impact of the GeneSight Psychotropic test (GeneSight) on psychiatric treatment response in 1,200 patients with major depressive disorder. GeneSight is one of the leading pharmacogenomics test to help guide medication selection for mental health disorders.

June 2016: OneOme announced about key business milestones in advance of launching its RightMed test. RightMed test is a cost-effective, comprehensive, personalized pharmacogenomics product which analyses 22 genes which provided at the point of care. The OneOme platform was co-developed and exclusively licensed from Mayo Clinic to bring pharmacogenomics into routine clinical care. OneOme’s RightMed test is currently in use by Mayo Clinic Center for individualized medicine. The test helps providers easily make personalized treatment decisions across more than 300 medications for more than 20 medical indications.

Global Pharmacogenomics Market - Competitive Analysis

Pharmacogenomics in recent years has used a new generation of technology approaches that has led to a revolution in the understanding of disease susceptibility and pathophysiology, providing enormous potential for novel therapeutic strategies.

However, with companies aiming to capture a considerable share of the market segment as early as possible, they are competing and experimenting with various advantage points. The best long-term growth opportunities for this sector can be captured by ensuring ongoing process improvements and financial flexibility to invest in the best strategies.

Get Attractive Discount @ .

The key players profiled in pharmacogenomics market report includes Myriad Genetics, Inc. (U.S.), 23andMe, Inc. (U.S.), Pathway Genomics (U.S.), GeneTech (U.S.), GeneDx. (U.S.), Future Science Group (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Assurex Health, Inc. (U.S.), OneOme (U.S.) and others.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Media Contact

Company Name: Market Research FutureContact Person: Akash Anand

Email: [email protected]
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune -
City: Pune
State: Maharashtra
Country: India


Page: 1

Related Keywords:Business,Health & Medicine,News & Current Affairs,Pharmaceuticals & Biotech,Science,
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter

  • Sanofi: Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis
  • Global Sleep Apnea Diagnostic and Therapeutic Devices: 2016/18-2024 Strategic Business Analysis & Forecast Report - mHealth-Enabled Sleep Tracking Devices Gain Ground
  • Blavatnik Family Foundation Provides $10 Million Gift to Mount Sinai to Support Mission of Advancing Women’s Health
  • Smart Contact Lenses Market 2018 Upgrading To Foster Growth At a CAGR of 10.4% | By Application; Continuous Glucose Monitoring, Intraocular Pressure Monitoring And Others Till 2023
  • Global Big Data in Healthcare Market: Analysis and Forecast, 2017-2025 (Focus on Components and Services, Applications, Competitive Landscape and Country Analysis)

  • Synovial Sarcoma Treatment Market, by Treatment Type Chemotherapy
  • Multiple New Vendor GPO Awards Position Keneric Healthcare to Increase Its Market Reach for Their Advanced Wound Care and Patient Cleansing Products Lines
  • RXi Pharmaceuticals Announces Positive Results from Phase 2 Trial with Samcyprone™ for the Treatment of Common Warts
  • Avicanna Inc. Proudly Hosts the "International Symposium on Cannabinoids & Medical Applications"
  • Stock-Sector Releases Interview with CEO of Helomics Discussing Precision Medicine with Precision Therapeutics

    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines